Skip to content

A Cohort Study on Acupuncture Combined with Intrauterine Perfusion of Autologous Platelet-Rich Plasma (PRP) for Thin Endometrium

A Cohort Study on Acupuncture Combined with Intrauterine Perfusion of Autologous Platelet-Rich Plasma (PRP) for Thin Endometrium

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025002115
Enrollment
Unknown
Registered
2025-11-04
Start date
2025-11-05
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thin endometrium

Interventions

Acupuncture plus PRP group:Acupuncture plus PRP

Sponsors

Sichuan Jinxin Xinan Women and Children's Hospital (Bisheng Campus)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of thin endometrium: Transvaginal ultrasound shows endometrial thickness <7 mm, and the ideal thickness (=7 mm) is not achieved in at least two menstrual cycles. 2. Age range: 20-40 years old, female. 3. Infertility diagnosis: Consistent with the World Health Organization (WHO) diagnostic criteria for infertility, and planning to receive ART treatment (such as in vitro fertilization-embryo transfer, IVF-ET). 4. Normal hormone levels: Basal hormone levels (FSH, LH, E2) within normal ranges, without severe endocrine diseases. 5. Informed consent signed: Patients voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Uterine cavity abnormalities: Severe intrauterine adhesions, endometrial polyps, uterine fibroids (affecting uterine cavity morphology), or other uterine cavity lesions. 2. Severe systemic diseases: Such as severe cardiovascular diseases, hepatic/renal insufficiency, immune system diseases, etc. 3. Infections or inflammations: Active acute or chronic reproductive system infections (e.g., pelvic inflammatory disease, active endometriosis). 4. Coagulation disorders: Bleeding tendency or ongoing anticoagulant therapy. 5. Malignant tumors: History of or current malignant tumors. 6. Mental illnesses: Severe mental disorders or inability to cooperate with treatment. 7. Allergy history: Allergy to PRP or acupuncture treatment. 8. Recent use of hormonal drugs: Use of hormonal drugs (e.g., estrogen, progesterone) within 3 months prior to study initiation. 9. Others: Other conditions deemed unsuitable for participation by the researcher.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;Uterine Artery Pulsatility Index;

Secondary

MeasureTime frame
endometrium thickness;Uterine Artery Resistance Index;Uterine Artery Systolic Peak Velocity/Diastolic End Velocity Ratio;Endometrial Vascularization Index;embryo implantation rate;Uterine Flow Index;

Countries

China

Contacts

Public ContactZheng Xiaoyan

Sichuan Jinxin Xinan Women and Children's Hospital (Bisheng Campus)

zxy13880756463@163.com13880756463

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026